Merck & Co., Inc. has received clearance for Winrevair (sotatercept) from the European Commission (EC) exactly five months after it was approved in the US, where the commercial launch to date has exceeded expectations. The firm is planning to launch Winrevair in European markets later this year, likely starting in Germany.
Merck’s Winrevair Approved For PAH In Europe As Initial US Launch Progresses
Q1 Revenue Totaled $70m, 60% From Stocking
Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.
More from New Products
• By
The Swiss giant has inked a deal potentially worth $5.30bn with Zealand to access the Danish biotech's long-acting amylin analog petrelintide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
Pharma revenues are going to fall this year as a result of deeper generic competition for the German group’s top-selling drug, Xarelto, but it should return to growth from 2027 onwards.
• By
The company sees a potential billion-dollar market opportunity in its approved indications and is launching the drug in what an exec called “a very targeted fashion” at a recent conference.